Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide. “We feel that a product like an oral, orforglipron, could serve a significant ...

The GLP-1 ad wars “Healthy Skepticism” comes weeks after Eli Lilly competitor and Ozempic-maker Novo Nordisk launched a print ...

At the 2024 Academy Awards, Eli Lilly, the manufacturer of blockbuster ... Noom Taps Rachel Mahoney As Chief Brand Officer Amid GLP-1 Expansion "As a knockoff copy of a prescription drug, the ...

Novo Nordisk A/S NVO has declared that its GLP-1 drugs for chronic obesity ... Taking a page from Eli Lilly and their LillyDirect online pharmacy, Novo Nordisk launched NovoCare Pharmacy, its ...

Regarding weight loss, Lilly in June 2023 unveiled phase 2 data showing orforglipron helped patients with obesity lose up to 14.7% of their body weight at 36 weeks compared to placebo. While those ...

Eli Lilly is growing ... Novo’ Nordisks established brand and global scale could still claw back share, especially overseas. Lilly’s chances of leading the GLP-1 race long-term are higher ...

Eli Lilly releases cheaper vials of the weight-loss drug for self-paying patients and cuts the price of two existing doses.

Teladoc (TDOC) shares are climbing on Thursday after the healthcare company announced its deal with Eli Lilly's (LLY) direct-to-consumer pharmacy partner Lilly Direct. The deal is set to streamline ...

Novo Nordisk is intervening in the lawsuit filed by a drug compounders trade group against the FDA over the agency’s decision ...

Feb 20 - Eli Lilly (LLY, Financial) is set to pivot its focus beyond obesity after a monumental windfall from its GLP-1 drugs. At its February monthly meeting, Chief Scientific Officer Dan Skovronsky ...

Teladoc Health has partnered with Eli Lilly's LillyDirect and pharmacy provider GiftHealth to expand access to Zepbound, a GLP-1 drug prescribed for weight loss. The partnership allows Teladoc ...